Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis

Susanna Colli, Sonia Eligini, Mariagrazia Lalli, Marina Camera, Rodolfo Paoletti, Elena Tremoli

Research output: Contribution to journalArticle

Abstract

We examined the effect of fluvastatin, the first entirely synthetic 3- hydroxy-3-methylglutaryl coenzyme. A reductase inhibitor that is structurally different from other vastatins, on tissue factor (TF) expression in human macrophages spontaneously differentiated in culture from blood monocytes. Fluvastatin decreased TF activity in a dose-dependent manner (1 to 5 μmol/L) in both unstimulated and lipopolysaccharide-stimulated macrophages and this reduction paralleled the decrease in immunologically recognized TF protein. The same results were obtained with another lipophilic vastatin, simvastatin but not with hydrophilic pravastatin. The reduction in TF expression was also observed in macrophages enriched in cholesterol after exposure to 50 μg/mL acetylated low density lipoprotein. The inhibitory effect of fluvastatin on TF activity and antigen was fully reversible by coincubation with 100 μmol/L mevalonate or 10 μmol/L all-trans-geranylgeraniol but not with dolichol, farnesol, or geraniol. Suppression of TF antigen and activity was accompanied by a diminution in TF mRNA levels, which was completely prevented by mevalonate. Furthermore, fluvastatin impaired bacterial lipopolysaccharide- induced binding of c-Rel/p65 heterodimers to a κB site in the TF promoter, indicating that this drug influences induction of the TF gene. We conclude that lipophilic vastatins inhibit TF expression in macrophages, and because this effect is prevented by mevalonate and geranylgeraniol, a geranylgeranylated protein plays a crucial role in the regulation of TF biosynthesis. The suppression of TF in macrophages by vastatins indicates a potential mechanism by which these drugs interfere with the formation and progression of atherosclerotic plaque as well as thrombotic events in hyperlipidemic patients.

Original languageEnglish
Pages (from-to)265-272
Number of pages8
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume17
Issue number2
Publication statusPublished - 1997

Fingerprint

Thromboplastin
fluvastatin
Macrophages
Mevalonic Acid
Lipopolysaccharides
vastatin
Farnesol
Dolichol
Antigens
Pravastatin
Simvastatin
Coenzymes
Atherosclerotic Plaques
Pharmaceutical Preparations
Monocytes
Oxidoreductases
Proteins
Cholesterol

Keywords

  • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
  • atherosclerosis
  • isoprenoids
  • procoagulant activity
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Vastatins inhibit tissue factor in cultured human macrophages : A novel mechanism of protection against atherothrombosis. / Colli, Susanna; Eligini, Sonia; Lalli, Mariagrazia; Camera, Marina; Paoletti, Rodolfo; Tremoli, Elena.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 17, No. 2, 1997, p. 265-272.

Research output: Contribution to journalArticle

@article{2b38b2f3a01b4a178f45d46a3f4fc3b7,
title = "Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis",
abstract = "We examined the effect of fluvastatin, the first entirely synthetic 3- hydroxy-3-methylglutaryl coenzyme. A reductase inhibitor that is structurally different from other vastatins, on tissue factor (TF) expression in human macrophages spontaneously differentiated in culture from blood monocytes. Fluvastatin decreased TF activity in a dose-dependent manner (1 to 5 μmol/L) in both unstimulated and lipopolysaccharide-stimulated macrophages and this reduction paralleled the decrease in immunologically recognized TF protein. The same results were obtained with another lipophilic vastatin, simvastatin but not with hydrophilic pravastatin. The reduction in TF expression was also observed in macrophages enriched in cholesterol after exposure to 50 μg/mL acetylated low density lipoprotein. The inhibitory effect of fluvastatin on TF activity and antigen was fully reversible by coincubation with 100 μmol/L mevalonate or 10 μmol/L all-trans-geranylgeraniol but not with dolichol, farnesol, or geraniol. Suppression of TF antigen and activity was accompanied by a diminution in TF mRNA levels, which was completely prevented by mevalonate. Furthermore, fluvastatin impaired bacterial lipopolysaccharide- induced binding of c-Rel/p65 heterodimers to a κB site in the TF promoter, indicating that this drug influences induction of the TF gene. We conclude that lipophilic vastatins inhibit TF expression in macrophages, and because this effect is prevented by mevalonate and geranylgeraniol, a geranylgeranylated protein plays a crucial role in the regulation of TF biosynthesis. The suppression of TF in macrophages by vastatins indicates a potential mechanism by which these drugs interfere with the formation and progression of atherosclerotic plaque as well as thrombotic events in hyperlipidemic patients.",
keywords = "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atherosclerosis, isoprenoids, procoagulant activity, thrombosis",
author = "Susanna Colli and Sonia Eligini and Mariagrazia Lalli and Marina Camera and Rodolfo Paoletti and Elena Tremoli",
year = "1997",
language = "English",
volume = "17",
pages = "265--272",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Vastatins inhibit tissue factor in cultured human macrophages

T2 - A novel mechanism of protection against atherothrombosis

AU - Colli, Susanna

AU - Eligini, Sonia

AU - Lalli, Mariagrazia

AU - Camera, Marina

AU - Paoletti, Rodolfo

AU - Tremoli, Elena

PY - 1997

Y1 - 1997

N2 - We examined the effect of fluvastatin, the first entirely synthetic 3- hydroxy-3-methylglutaryl coenzyme. A reductase inhibitor that is structurally different from other vastatins, on tissue factor (TF) expression in human macrophages spontaneously differentiated in culture from blood monocytes. Fluvastatin decreased TF activity in a dose-dependent manner (1 to 5 μmol/L) in both unstimulated and lipopolysaccharide-stimulated macrophages and this reduction paralleled the decrease in immunologically recognized TF protein. The same results were obtained with another lipophilic vastatin, simvastatin but not with hydrophilic pravastatin. The reduction in TF expression was also observed in macrophages enriched in cholesterol after exposure to 50 μg/mL acetylated low density lipoprotein. The inhibitory effect of fluvastatin on TF activity and antigen was fully reversible by coincubation with 100 μmol/L mevalonate or 10 μmol/L all-trans-geranylgeraniol but not with dolichol, farnesol, or geraniol. Suppression of TF antigen and activity was accompanied by a diminution in TF mRNA levels, which was completely prevented by mevalonate. Furthermore, fluvastatin impaired bacterial lipopolysaccharide- induced binding of c-Rel/p65 heterodimers to a κB site in the TF promoter, indicating that this drug influences induction of the TF gene. We conclude that lipophilic vastatins inhibit TF expression in macrophages, and because this effect is prevented by mevalonate and geranylgeraniol, a geranylgeranylated protein plays a crucial role in the regulation of TF biosynthesis. The suppression of TF in macrophages by vastatins indicates a potential mechanism by which these drugs interfere with the formation and progression of atherosclerotic plaque as well as thrombotic events in hyperlipidemic patients.

AB - We examined the effect of fluvastatin, the first entirely synthetic 3- hydroxy-3-methylglutaryl coenzyme. A reductase inhibitor that is structurally different from other vastatins, on tissue factor (TF) expression in human macrophages spontaneously differentiated in culture from blood monocytes. Fluvastatin decreased TF activity in a dose-dependent manner (1 to 5 μmol/L) in both unstimulated and lipopolysaccharide-stimulated macrophages and this reduction paralleled the decrease in immunologically recognized TF protein. The same results were obtained with another lipophilic vastatin, simvastatin but not with hydrophilic pravastatin. The reduction in TF expression was also observed in macrophages enriched in cholesterol after exposure to 50 μg/mL acetylated low density lipoprotein. The inhibitory effect of fluvastatin on TF activity and antigen was fully reversible by coincubation with 100 μmol/L mevalonate or 10 μmol/L all-trans-geranylgeraniol but not with dolichol, farnesol, or geraniol. Suppression of TF antigen and activity was accompanied by a diminution in TF mRNA levels, which was completely prevented by mevalonate. Furthermore, fluvastatin impaired bacterial lipopolysaccharide- induced binding of c-Rel/p65 heterodimers to a κB site in the TF promoter, indicating that this drug influences induction of the TF gene. We conclude that lipophilic vastatins inhibit TF expression in macrophages, and because this effect is prevented by mevalonate and geranylgeraniol, a geranylgeranylated protein plays a crucial role in the regulation of TF biosynthesis. The suppression of TF in macrophages by vastatins indicates a potential mechanism by which these drugs interfere with the formation and progression of atherosclerotic plaque as well as thrombotic events in hyperlipidemic patients.

KW - 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

KW - atherosclerosis

KW - isoprenoids

KW - procoagulant activity

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0031025656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031025656&partnerID=8YFLogxK

M3 - Article

C2 - 9081680

AN - SCOPUS:0031025656

VL - 17

SP - 265

EP - 272

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 2

ER -